Media Kit and Additional Info

Media Kit

About the Author:  Dana Brantley-Sieders, PhD, has been a biomedical breast cancer researcher for over twenty years, investigating molecular mechanisms that regulate breast cancer growth and metastasis. She is also an author, advocate, and breast cancer survivor. She resides in Nashville, Tennessee.

Name: Dana Brantley Sieders, PhD

Email: fortheloveofyourboobs@gmail.com

Website: https://talkingtatas.com/

Twitter: @DBSieders

Facebook: https://www.facebook.com/DrSieders

Literary Agent: Barbara Collins-Rosenberg (http://rosenberggroup.com/)

Editor: Suzanne Staszak-Silva, Rowman & Littlefield (https://rowman.com/)

Sample Q&A:

  1. Will we ever cure breast cancer? Will we ever cure cancer?
  2. What is the most surprising thing you learned about breast cancer as a patient that you didn’t know from your research?
  3. Do you regret not having a mastectomy after your diagnosis since you were later diagnosed with residual disease?
  4. What is the future of cancer research? Where do you think the next big advances will come from?
  5. What advice would you give to a newly diagnosed breast cancer patient?
  6. What was the most difficult part of the process for you, from diagnosis, surgery, or treatments?
  7. What can we do to improve equity and equality in breast cancer care?
  8. What aspects of breast cancer do you wish the public was more aware of?
  9. What will you do if your breast cancer recurs?
  10. What advice would you give young women entering the field of breast cancer research?

Press Release:

Headline: Talking to My Tatas: All You Need to Know from a Breast Cancer Researcher and Survivor provides accessible science and health information for the love of your boobs, especially when they have cancer.

Short Synopsis: Talking To My Tatas gives breast cancer patients and survivors easy access to the latest science from breast cancer researcher and survivor Dana Brantley-Sieders. From surgery, tumor genomic testing, and cutting-edge therapies to mental health, sexual health, and avoiding pseudoscience scams, she delivers the goods with a side of humor and hope.

Contact Details: For more information or to request a review copy, contact Dana Brantley-Sieders, fortheloveofyourboobs@gmail.com

Features Angle: Based on a true story from the laboratory bench to her own bedside, Dr. Brantley-Sieders demystifies breast cancer by providing accessible science and health information for the more than three-hundred thousand people diagnosed with this disease each year in the United States and their caregivers, as well as patients and survivors around the world.

Book Details:             

Publication Date: February 8, 2022

Publisher: Rowman & Littlefield

Price: Hardback $36, eBook $34     

Available from print and eBook retailers, including: Amazon, Barnes&Noble, Google Books, Apple.com/apple-books, Booksamillion.com, Bookshop.org, Powells.com, and Indiebound.com and other retailers.

Pre-order hardback from Rowman & Littlefield: https://rowman.com/ISBN/9781538155103/Talking-to-My-Tatas-All-You-Need-to-Know-from-a-Breast-Cancer-Researcher-and-Survivor

Published Articles:

Dana Brantley-Sieders, PhD. Tables Turned: From the Laboratory Bench to My Own Bedside. September 20, 2020. Momentum. https://momentum.vicc.org/2020/09/tables-turned/

Dana Brantley-Sieders, Ph.D. What I’ve learned as a breast cancer researcher and survivor. October 27, 2021. Main Street Nashville. https://www.mainstreet-nashville.com/life/health/what-ive-learned-as-a-breast-cancer-researcher-and-survivor/article_e689de82-31c3-11ec-a4a6-9736741cc9d4.html

Dana Brantley-Sieders, Ph.D. When Cancer Asked Me What I Was Made Of. Conquer Magazine. Patient Stories. Breast Cancer. October 2022. Volume 8. Issue 5. https://conquer-magazine.com/issues/2022/vol-8-no-5-october-2022/1911-when-cancer-asked-me-what-i-was-made-of

Interviews:

Let’s Talk About Breasts with Dr. Dana Brantley-Sieders. Ronei Harden-Mornoey. October 23, 2020. YouTube.

Tampa Bay Reads segment featuring Dr. Dana Brantley-Sieders. Linda Hurtado, Fox13 News. October 26, 2022.

Selected Scientific Publications:

Vaught, D., B., Merkel, A.R., Lynch, C.C., Edwards, J., Noor Tantawy, M. N., Hilliard, T., Peterson, T., Johnson, R.W., Sterling, J.A. and Brantley-Sieders, D.M.* (2021) EphA2 is a Clinically Relevant Target for Breast Cancer Bone Metastatic Disease. Journal of Bone and Mineral Research JMBR Plus. Mar 9;5(4):e10465. doi: 10.1002/jbm4.10465. eCollection 2021 Apr. PMID: 33869989. PMCID: PMC8046157. *Corresponding author.

Song, W., Kim, L.C., Han, W., Hou, Y., Blackwell, T., Cheng, F., Brantley-Sieders, D.M.*, and Chen, J. (2020) Phosphorylation of PLCγ1 by EphA2 receptor tyrosine kinase promotes tumor growth in lung cancer. Molecular Cancer Research, 18: 1735-1743. PMID: 32753469. *Co-corresponding author.

Werfel, T.A., Hicks, D.J., Rahman, Burshra, R., Bendeman, W., Duvernay, M., Maeng, J.G.,     Hamm, H., Lavieri, R., Joly, M., Pulley, J., Elion, D., Brantley-Sieders, D., and Cook, R. (2020) Repurposing of a thromboxane receptor inhibitor based on a novel role in metastasis identified by Phenome Wide Association Study. Molecular Cancer Therapeutics, 19: 2454-2464. PMID: 33033174.

Shiuan, E., Inala, A., Wang, S., Song, W., Youngblood, V., Chen, J. and Brantley-Sieders, D.M. * (2020) Host deficiency in ephrin-A1 inhibits breast cancer metastasis [version1; peer review 3, approved]. F1000Research, 9:217 (https://doi.org/10.12688/f1000research.22689.1)*Corresponding author.

Werfel, T.A., Wang, S., Jackson, M.A., Kavanaugh, T.E., Morrison-Joly, M., Lee, L., Hicks, D.J., Sanchez, V., Gonzales-Ericsson, P.I., Kilchrist, K.V., Dimobi, S.C., Brantley-Sieders, D. M., Cook, R.S., and Duvall, C. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res Jan 22. pii: canres.2388.2017. doi: 10.1158/0008-5472.CAN-17-2388. [Epub ahead of print]. PMID: 29358192.

Morrison Joly, M., Williams, M.M., Hicks, D.J., Jones, B., Sanchez, V., Young, C.D., Sarbassov, D.D., Muller, W.J., Brantley-Sieders, D.M., and Cook, R.S. (2017). Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. Breast Cancer Res 19: 74. doi: 10.1186/s13058-017-0868-8. PMID: 28666462. PMCID: PMC5493112.

Song, W., Hwang, Y., Youngblood, V., Cook, R.S., Balko, J., Chen, J., and. Brantley-Sieders, D.M.* (2017)Targeting EphA2 Impairs Cell Cycle Progression and Growth in Basal-like/triple- negative Breast Cancers. Oncogene 36:5620-5630. PMID: 28581527. PMCID: PMC5629103. *Corresponding author.

Youngblood VM, Kim LC, Edwards DN, Hwang Y, Santapuram PR, Stirdivant SM, Lu P, Ye F, Brantley-Sieders DM*, Chen J. (2016) The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer. Cancer Res 76: 1825-36. PMID: 26833123. PMCID: 4873477. *Co-corresponding author.

Morrison M.M., Young C.D., Wang S., Sobolik T., Sanchez V.M., Hicks D.J., Cook R.S., Brantley-Sieders D.M.* (2015) mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis. PLoS Genetics Jul 1;11(7):e1005291. doi: 10.1371/journal.pgen.1005291. PMID: 26132202. PMCID: 4488502. *Corresponding author.

Youngblood, V.Y., Wang, S., Song, W., Walter, D., Hwang, Y., Chen, J., and Brantley-Sieders, D.M.* (2015) Elevated Slit2 activity impairs VEGF-induced angiogenesis and tumor neovascularization in EphA2-deficient endothelium. Mol Cancer Res. 13: 524-37. PMID: 25504371. PMCID: PMC4416411. *Corresponding author.

Stanford, J.C., Young, C., Hicks, D., Owens, P., Williams, A., Vaught, D.B., Morrison, M.M., Lim, J., Williams, M., Brantely-Sieders, D.M., Balko, J.M., Tonetti, D., Earp, H.S. 3rd, and Cook, R.S. (2014) Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. Journal of Clinical Investigation. 124: 4737-52. PMID 25250573. PMCID: PMC4347249.

Brantley-Sieders, D.M., Fan, K.H., Deming-Halverson, S.L., Shyr, Y., and Cook, R.S. (2012) Local breast cancer spatial patterning: a tool for community health resource allocation to address local disparities in breast cancer mortality. PLoS One 7: e45238. PMID 23028869. PMCID: PMC3460936.

Brantley-Sieders, D.M., Jiang, A., Sarma, K., Badu-Nkansah, A., Walter, D.K., Shyr, Y., and Chen, J. (2011) Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome.  PLoS One 6: e24426. PMID: 21935409. PMCID: PMC3174170.

Zhuang, G., Brantley-Sieders, D. M., Vaught, D., Yu, J., Xie, Lu, Wells, S., Jackson, D., Rebecca Cook, Carlos Arteaga, and Chen, J. (2010) A determining role of the EphA2 receptor tyrosine kinase in resistance to trastuzumab therapy Cancer Research 70: 299-308. PMCID: PMC3859619.

Vaught, D., Chen, J. and Brantley-Sieders, D.M.* (2009) Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase. Molecular Biology of the Cell 20: 2572-81. PMID: 19321667. PMCID: PMC2682598. *Corresponding author.

Brantley-Sieders, D.M., Zhuang, G., Hicks, D., Fang, W.B., Hwang, Y., Cates,   J.M., Coffman, K., Jackson, D., Bruckheimer, E., Muraoka-Cook, R.S., and Cheng, J. (2008) The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. Journal of Clinical Investigation 118: 64-78.  PMID: 18387945. PMCID: PMC2129239.

Brantley-Sieders, D. M., Fang, W. B., Hicks, D. J., Zhuang, G., Shyr, Y., and Chen, J. (2005). Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J 19: 1884-6. PMID: 16166198.

Brantley, D. M., Cheng, N., Thompson, E. J., Lin, Q., Brekken, R. A., Thorpe, P. E., Muraoka, R. S., Pozzi, A., Jackson, D., Lin, C., and Chen, J.  (2002). Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.  Oncogene 21: 7011-26. PMID: 12370823.

Brantley, D.M., Chen, C.-L., Muraoka, R.S., Bushdid, P. B., Bradberry, J. L., Kittrell, F., Medina, D., Matrisian, L. M., Kerr, L.D., and Yull, F. E.  Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium.  (2001) Molecular Biology of the Cell 12: 1445-55. PMID: 11025216.